Vendor source

Reviewed 30 Jun 2026

Completeness Comprehensive (81%)

NeuroQuant

Cortechs.ai

NeuroQuant® is a fully automated advanced imaging software that provides segmentation and quantification from brain MRI, revealing various biomarkers. Values are compared to a unique normative database of patients of the same age and sex and similar intracranial volume to aid in making clinical decisions regarding neurodegenerative diseases.

Supported by 6 papers

NeuroQuant thumbnail 1
NeuroQuant thumbnail 2
NeuroQuant thumbnail 3
NeuroQuant thumbnail 4
NeuroQuant thumbnail 5
NeuroQuant thumbnail 6
NeuroQuant thumbnail 7
NeuroQuant thumbnail 8
NeuroQuant thumbnail 9
NeuroQuant thumbnail 10
NeuroQuant thumbnail 11
NeuroQuant thumbnail 12
NeuroQuant thumbnail 13
NeuroQuant thumbnail 14
NeuroQuant thumbnail 15
NeuroQuant thumbnail 16

Key Features

  • Brain change data
  • Brain region quantification (75 structures)
  • Custom report options
  • Dynamic atlas
  • Normative data comparisons

General Information

Product name

NeuroQuant

Modality

MR

Main task

Not specified

Subspeciality

Neuro

Disease targeted

Neurodegenerative diseases

Regulatory Information

CE Certification

Pathway:

MDD

Class:

Class IIa

Verified by Health AI Register

FDA Certification

Pathway:

510(k) cleared

Class:

Class II

Verified by Health AI Register

Other certifications

Not specified

Technical Specifications

Patient population age

Not specified

Input

3D T1 sagittal MR sequence

Input format

DICOM

Output

segmentation overlays, brain change overlay, quantitative report with structure volumes, structure change data, and normative comparisons

Output format

DICOM

Integration

Integration via AI marketplace or distribution platform, Stand-alone third party application, Stand-alone webbased

Deployment

Cloud-based, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker)

Trigger for analysis

On demand, triggered by a user through e.g. a button click, image upload

Processing time

> 10 minutes

Population

Patients aged 3-100 with suspicion of atrophy, edema, or abnormal brain development

Market Presence

On market since

08-2006

AI Platforms

Resellers

Getz Healthcare, GMP, Olea Medical

Countries present

43

Paying clinical customers

Not specified

Research/test users

Not specified

Pricing Information

Pricing model

Subscription

Based on

Number of analyses, Number of installations

Source: Vendor | First published: May 2, 2024 | Last updated: Jun 30, 2026